In patients with peripheral arterial disease (PAD), prophylaxis is indicated after any vascular intervention to prevent acute thrombotic occlusion, as well as recurrent stenosis due to intimal hyperplasia or progressive arteriosclerosis. In contrast to coronary and carotid interventions, there is no standardized regime established or even recommended after peripheral arterial interventions. Coronary interventions are performed by cardiologists only, while peripheral interventions are conducted by radiologists, cardiologists, angiologists, and vascular surgeons. However, radiologists and vascular surgeons are not trained in the management of atherosclerotic risk factors.
In this editorial, I discuss the lack of a specific prophylaxis protocol after transcatheter interventions and bypass surgery. Issues to be considered are whether postinterventional prophylaxis depends on the type of transluminal or surgical procedure and whether such a regime can be the same in each patient. Finally, the need for a comprehensive concept is examined, including the management of atherosclerotic risk factors.
PERIPHERAL TRANSCATHETER INTERVENTIONS
It remains unclear why postinterventional prophylaxis after peripheral angioplasty has played such a minor role in the literature compared to coronary interventions. Even in the few ''milestone'' studies, the investigators were not interested in postinterventional prophylaxis. Tetteroo et al., 1 in the largest randomized study on primary stent placement versus primary angioplasty in iliac arteries, wrote in 1998 that ''postinterventional therapy was done in accordance to the preference of the individual family doctors.'' This fact is even more incomprehensible because in 1994 the Antiplatelet Trialists' Collaboration reported that allocation to antiplatelet therapy was associated with a highly significant 43% reduction in vascular occlusion (pϽ0.00001). 2 Peripheral intervention including stent placement usually does not require vitamin-K antagonists. In 1995, White et al. 3 published a small series including 32 patients treated with Strecker stents for femoropopliteal lesions. The primary patency rate was 75% at 18 months without vitamin-K antagonists. Watson and Bergqvist 4 analyzed the literature in 2000. On the basis of 6 double-blind studies, they concluded that a significant benefit of aspirin in 1 placebo-controlled study was balanced by no apparent benefit in another study. A dose-dependent effect of aspirin or a difference in outcome comparing platelet inhibitors and oral anticoagulants was not found. Up to the present, no further clarifying studies have been performed, and postinterventional prophylaxis still varies.
In 2003, Bonvini et al. 5 reported the results of endovascular brachytherapy and stenting of 94 femoropopliteal arteries after publication of a positive notice from the Food and Drug Administration regarding intracoronary stenting and brachytherapy. 6 All patients re-ceived aspirin (100 mg/d) and clopidogrel (75 mg/d) for an unlimited time. Late thrombotic occlusions occurred in 6 patients concomitantly with reduction/cessation of the antithrombotic therapy owing to side effects or noncompliance. In 2004, Grenacher et al. 7 published the results of a randomized multicenter study on primary stent placement versus angioplasty in the femoropopliteal segment. In this study, postinterventional prophylaxis was performed with intravenous heparin for 48 hours and aspirin (100 mg/d) for 6 months only. Both these studies showed technical feasibility, but the interventional procedures were not considered as a part of a long-term treatment concept. Their postinterventional prophylaxis aimed to prevent thrombotic occlusions only, but aspects of prevention of ongoing arteriosclerosis were not considered. According to the American Heart Association/American College of Cardiology (AHA/ACC) recommendation for ''Secondary Prevention for Patients with Coronary and Other Vascular Diseases,'' lifelong antiplatelet therapy is mandatory in every vascular patient. 8 Primary and secondary goals for lipid management were given. Therefore, it is surprising that studies on peripheral intervention rarely include information about lipid-lowering therapy or additional risk factor management.
Lipoprotein (a) levels of 59Ϯ11 mg/dL have been shown to be an independent risk factor for disease recurrence after peripheral angioplasty in the femoropopliteal area, but hyperlipidemia was not. 9 Schillinger et al. 10 also found no role for cholesterol in restenosis in a 2001 retrospective cohort study. In 168 consecutive patients who underwent successful PTA of the femoral and/or popliteal arteries, baseline C-reactive protein level (odds ratio [OR] 4.2, pϭ0.02) was an independent predictor of outcome, but not the classical risk factors of atherosclerosis. Such results are in contrast to coronary interventions, especially since simvastatin has been shown to have the potential to induce positive vascular remodeling and thus reduce the occurrence of restenosis in peripheral arteries. 11 Data regarding other risk factors are even more confusing. The lack of hypertension (pϭ0.01) was associated with restenosis at 12 months after femoropopliteal PTA in a study of 114 patients with symptomatic PAD. 12 Smoking 10 or more cigarettes daily was associated with a reduced rate of intermediateterm restenosis after lower limb interventions in an analysis of 650 patients undergoing PTA or stent placement. 13 Plasma levels of homocysteine did not influence the outcome of femoropopliteal angioplasty or subintimal angioplasty in 2 studies. 14,15
PERIPHERAL BYPASS PROCEDURES
Although peripheral bypass procedures have been performed for many more years than PTA, the modalities for postoperative treatment are still changing. To evaluate whether antithrombotic treatment in chronic PAD patients undergoing infrainguinal bypass surgery improves graft patency, limb salvage, and survival, Dö rffler-Melly et al. 16 performed a meta-analysis of 4 randomized controlled trials that evaluated vitamin-K antagonists versus no vitamin-K antagonists in 840 patients. Their results indicated that oral anticoagulation tendentiously favors graft patency (OR 0.77, 95% confidence interval [CI] 0.58 to 1.02) at 5 years without being significant. Two other studies comparing vitamin-K antagonists with aspirin or aspirin/dipyridamole supported evidence for a positive effect of vitamin-K antagonists on the patency of venous (OR 0.59 at 24 months, 95% CI 0.46 to 0.76) but not artificial grafts (OR 1.41 at 24 months, 95% CI 1.11 to 1.80). 17, 18 To evaluate whether antiplatelet treatment in symptomatic PAD patients undergoing infrainguinal bypass surgery improves graft patency, Dö rffler-Melly et al. 19 performed a second meta-analysis. In this, they found that the administration of a variety of platelet inhibitors improved venous and artificial graft patency compared to no treatment. However, analyzing the outcomes by graft type indicated that patients receiving a prosthetic graft were more likely to profit from administration of platelet inhibitors than those treated with a venous graft.
In 1998, Sarac et al. 20 published a prospective randomized trial on warfarin therapy in addition to aspirin (325 mg/d) in patients with infrainguinal bypasses. Three-year primary patency rates were significantly greater in the warfarin ϩ aspirin group than in the aspirin only group (74% versus 51%, pϭ0.04). The results are confirmed by a study from Johnson et al. 21 in 2002, but patients with vein bypasses and 8-mm grafts did not show any benefit from the combined therapy. Only prosthetic femoropopliteal grafts with a 6-mm diameter showed a significantly improved patency (71% versus 58%, pϭ0.02). In summary, antiplatelet therapy is indicated in all patients with peripheral bypasses. Patients with only small prosthetic infrainguinal and some infragenicular bypasses might benefit from vitamin-K antagonists. The Seventh American College of Chest Physicians Conference (ACCP) on Antithrombotic Treatment recommended combining antiplatelet agents and vitamin-K antagonists only in patients with a high risk for occlusion, but the criteria for defining ''high risk'' were not precisely specified. 22 The number of studies reporting the influence of atherosclerotic risk management on long-term outcome after bypass surgery is as low as those after peripheral angioplasty. In a study of 229 patients with prosthetic inflow treated additionally with autogenous infrainguinal bypass, hypertension (hazard ratio [HR] 3.41, 95% CI 1.65 to 7.05; pϭ0.001) was independently associated with bypass occlusion. 23 In 2004, Henke et al. 24 looked for the effects of secondary prevention on graft patency in 239 patients according to the AHA/ ACC recommendations. Antiplatelet agents or vitamin-K antagonists were taken by 93% of the patients, but statin drugs by only 56% and angiotensin-converting-enzyme (ACE) inhibitors by only 54%. Cumulative graft patency was 73%, limb salvage was 85%, and mortality was 9% over a mean follow-up of 17 months. Statin drugs were independently associated with increased graft patency (OR 3.7, 95% CI 2.1 to 6.4) and with a decreased amputation rate (OR 0.34, 95% CI 6.15 to 0.77). Kaplan-Meier analysis showed that ACE inhibitors were associated with lower mortality only (pϭ0.05).
The benefit of statins was also shown in a retrospective analysis of 172 consecutive patients who underwent primary autogenous infrainguinal reconstructions with a single segment of great saphenous vein. 25 Patients on statin drugs had higher assisted primary (94%Ϯ2% versus 83%Ϯ5%, pϽ0.02) and secondary (97%Ϯ2% versus 87%Ϯ4%, pϽ0.02) graft patency rates at 2 years. The risk of graft failure was 3.2-fold higher (95% CI 1.04 to 10.04) for the control group. Interestingly, preoperative cholesterol levels (available in 47% of patients) were statistically not different between groups.
COMMENTS
All doctors have to cooperate closely to prolong patency. Prophylaxis after peripheral vascular procedures cannot be seen as an independent treatment concept; it should be an integral part of the entire treatment strategy for every single patient. Antithrombotic therapy is only one aspect, and the data from the literature are insufficient to formulate a standardized regime. The 7 th ACCP consensus statements recommend antiplatelet therapy in patients after peripheral catheter-based intervention only because of its protective properties for coronary and cerebrovascular events. 22 Cardiologists learned long ago that patency rates should not be reported without incorporating the mechanisms for secondary vascular disease prevention. Studies reporting outcome after coronary interventions today always include data about medication and risk factor management at the time of intervention and during follow-up. This is possible because cardiologists often perform interventions and then follow these patients in the long term. On the other hand, peripheral vascular interventions are most frequently performed by surgeons or radiologists, specialists who are not as familiar with protocols for secondary prevention of atherosclerosis and who do not customarily follow patients but refer them back to their primary care physicians. Due to this gap in responsibility, continuous postinterventional treatment is not guaranteed.
One example of the low awareness for atherosclerotic risk factors on the part of peripheral interventionists might be found in the excellent 2004 article from Gallino et al. 26 In this study on endovascular brachytherapy and ϩ a lipid-lowering drug ϩ an ACE inhibitor (preferred) for antihypertensive therapy Limited duration: clopidogrel after stent placement Vitamin-K antagonists after peripheral bypass in patients with high risk for occlusion, as long as the bypass graft remains patent (always in addition to aspirin)
ࡗ ࡗ
This concept considers in part the AHA/ACC recommendation 8 and the sparse published results for peripheral interventions. This regime should be adopted by all specialties in every treatment protocol after all peripheral vascular procedures until new studies provide better evidence.
probucol, the authors said, ''. . . concomitant lipid-lowering agents were allowed according to the clinical need.'' What is the clinical need if not the patency of the treated segment? ''Was allowed'' sounds as if there might be undesirable side effects. I would have expected them to strongly recommend such a therapy to prevent patency, not just to ''allow'' it. The generally neglectful attitude of doctors to PAD has been described, which adds to this problem. A study from Nass et al. 27 showed that patients presenting for vascular surgery have a high prevalence of modifiable risk factors that are not being adequately managed. They analyzed the prevalence of cardiac risk factors and preventive pharmacological therapy in 82 patients undergoing carotid surgery and 155 patients having lower extremity bypass between July 1996 and February 1999. Patients with lower extremity disease were less likely than those with carotid disease to be on aspirin (45% versus 62%), a lipid-lowering agent (30% versus 45%, pϽ0.05), or a beta-blocker (26% versus 39%, pϽ0.05).
McDermott et al. 28 compared rates of therapy for atherosclerotic risk factors between patients with lower extremity PAD and patients with coronary artery disease (CAD) in 1997. Their 349 consecutive patients were interviewed by telephone for medical history, as well as therapies prescribed and recommended by their physicians. Among patients J ENDOVASC THER 2006; 13:32-38 with hypercholesterolemia, more CAD patients were taking cholesterol-lowering drugs (58% versus 46%, pϭ0.08) and more CAD patients recalled a physician's instruction to follow a low-fat, low-cholesterol diet (94% versus 83%, pϭ0.01).
The same group published the results of a national survey of general internists, family practitioners, cardiologists, and vascular surgeons documenting practice behavior, knowledge, and attitudes regarding atherosclerotic risk factor reduction in PAD patients. 29 Average low-density lipoprotein levels at which physicians ''almost always'' initiated lipidlowering drugs were 122Ϯ24 mg/dL, 136Ϯ29 mg/dL, and 150Ϯ24 mg/dL for patients with CAD, PAD, or no disease, respectively (pϽ0.001). Compared to other specialties, cardiologists had the lowest thresholds, whereas vascular surgeons had the highest thresholds for initiating cholesterol-lowering interventions for PAD patients. Similar data were reported by Cambou et al. 30 From March to July 1999, 940 private cardiologists in France recruited 100,429 patients, of whom 30% had a previous history of atherothrombotic disease. The prevalence of patients with a previous history of myocardial infarction or PAD was 19.7% and 10.7%, respectively. More than 90% of the patients received antithrombotic therapy, especially an antiplatelet agent. Thienopyridine represented 17.9% of the prescriptions. The prescription rate of statins in 59% of the patients after myocardial infarction was lower than expected, but obviously higher than in PAD (47%). In Germany, we surveyed radiologists, cardiologists, and angiologists about how they recommended or performed postinterventional short and longterm prophylaxis. 31 All used antiplatelet drugs for long-term prophylaxis, accounting for up to 90% of all patients. As the Figure shows, radiologists used clopidogrel less often and heparin more frequently for short-term prophylaxis and almost no statins for long-term prophylaxis. Of course, interventionists are primarily responsible for the success and complication rates of the interventions they perform, but their work is also judged by the long-term patency rates.
CONCLUSION
Patients who have undergone surgical and transcatheter peripheral vascular procedures are undertreated with respect to antiatherosclerotic medications. The reasons are the low awareness of the doctors for PAD, the lack of clinical trials in these specific territories, and the treatment of PAD by specialists who are not taught atherosclerosis risk management. Institution of consensus guidelines concerning postinterventional prophylaxis should be considered by all vascular specialists. Lifelong antiplatelet and lipid-lowering therapy is mandatory in all patients to increase patency rates (Table) . ACE inhibitors might be useful. Although these drugs are predominantly given to reduce coronary and cerebrovascular mortality, their effect on patency after peripheral procedures has been largely ignored. Thus, well designed studies should be initiated to obtain sufficient evidence. Moreover, studies reporting the outcome after peripheral procedures should be expected to include detailed data regarding the management strategies for risk factor reduction.
